Nanexa AB
NANEXA.STNanexa AB leverages its innovative PharmaShell® technology to create long-acting injectable drug formulations, aiming to transform treatment paradigms by enhancing patient convenience and adherence. The company's lead program, NEX-20, is a long-acting version of azacitidine for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), currently in Phase 1 development. With a public listing and strategic collaborations, Nanexa is positioned to advance its pipeline and expand its platform applications across multiple therapeutic areas.
NANEXA.ST · Stock Price
Historical price data
AI Company Overview
Nanexa AB leverages its innovative PharmaShell® technology to create long-acting injectable drug formulations, aiming to transform treatment paradigms by enhancing patient convenience and adherence. The company's lead program, NEX-20, is a long-acting version of azacitidine for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), currently in Phase 1 development. With a public listing and strategic collaborations, Nanexa is positioned to advance its pipeline and expand its platform applications across multiple therapeutic areas.
Technology Platform
PharmaShell® platform using atomic layer deposition (ALD) technology to create ultra-thin, biocompatible ceramic coatings on drug particles for controlled release over extended periods.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| NEX-20A | Multiple Myeloma | Phase 1 | |
| NEX-18a injection + Azacitidine Injection | Myelodysplastic Syndromes (MDS) | Phase 1 | |
| NEX-22A, a prolonged release formulation of liraglutide | Type 2 Diabetes | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes with other drug delivery technology companies like Camurus and MedinCell in the long-acting injectable space. Differentiation through precise ALD-based PharmaShell® technology and focus on reformulating established drugs with proven efficacy.
